Momenta Pharmaceuticals, Inc. (Public, NASDAQ:MNTA)

Discussion in 'Men's Economics' started by Michael Scally MD, Sep 10, 2011.

  1. Michael Scally MD

    Michael Scally MD Doctor of Medicine

    I think this stock is a as close to a sure thing if there ever was. MNTA is the sole generic provider (with partner NVS) of Lovenox. They have been so now for one year. Lovenox is a $2 BILLION drug, which is now ~50% generic. MNTA has about ~45% of receipts. In 2Q 20011, they received $85 million as their portion. MNTA has ~$350 Million. At the current $16.00 price you're only paying $9.00/share for the business (as MNTA has approximately $7/share of net cash). Thus on a market capitalization (net of cash) MNTA is being valued at $475M. At the end of 2011, they will have ~$450 Million (After Tax).

    The reason the share price is not higher is due to the overhang of TEVA's supposed generic Lovenox. NOT GONNA HAPPEN.

    A SURE FIRE WAY TO MAKE $$$MONEY$$$ IS TO TRADE AROUND $16.


    Momenta Pharmaceuticals is a biotech firm that was borne out of research done at MIT that developed a process for the sequencing and characterization of complex sugar molecules. Momenta was founded by two MIT faculty members, Ram Sasisekharan and Ganesh Venkataraman, who worked in collaboration to develop this technology, using this as the platform for Momenta at its founding in 2001. Sasisekharan currently serves as the director of a joint Health Sciences and Technology program between Harvard and MIT.

    Momenta’s main competitive advantage is the technology platform that the company is based on the characterization and sequencing of extremely complex sugar molecules.

    Momenta Pharmaceuticals, Inc. (Public, NASDAQ:MNTA) Momenta [CC: Momenta Pharmaceuticals, Inc. - Events & Presentations ]/ Momenta Pharmaceuticals, Inc.: NASDAQ:MNTA quotes & news - Google Finance / SEC: EDGAR Search Results

    2011 10-Q: http://www.sec.gov/Archives/edgar/data/1235010/000110465911044121/a11-13885_110q.htm

    Momenta Pharmaceuticals CEO Discusses Q2 2011 Results - Earnings Call Transcript
    Momenta Pharmaceuticals CEO Discusses Q2 2011 Results - Earnings Call Transcript - Seeking Alpha

    MNTA’s GS webcast today (35 minutes) is a good listen, especially with respect to the FoB arena. Goldman Sachs 32nd Annual Global Healthcare Conference


    Five bullish things for MNTA that could occur at any time:

    • FDA approval of generic Copaxone.

    • A partnership deal for an FoB program.

    • A partnership deal for M402 (or, less likely, for M118).

    • Monetization of MNTA’s Lovenox income stream.

    • A buyout offer.


    Copaxone

    • Aug-Sep 2011: Possible ruling re Copaxone mini-trial on inequitable conduct argument. (Mini-trial will be completed in Jul 2011; the Judge will presumably rule on inequitable conduct before the start of the Copaxone trial on other arguments, although this is not a legal requirement.)

    • 7-Sep-2011: Copaxone patent trial begins on all arguments other than inequitable conduct.

    • Timing uncertain: FDA action on Copaxone ANDA.


    Lovenox

    • 4-Aug-2011: MNTA’s 2Q11 financial results and CC.

    • 4-Feb-2013 (not a typo): Start of NVS/MNTA’s patent-infringement suit against Teva. We may presume that NVS/MNTA would ask the Court for a preliminary injunction against Teva in the event that Teva were to get FDA approval for generic Lovenox. Therefore, the fact that Teva has agreed to a drawn-out timeline in which a trial could not start until 2013 suggests that Teva has no expectation of getting FDA approval in the next two years. For readers of this board, this is hardly surprising, of course.




    I realize one of your concerns is possible litigation when it comes to a drug. In fact, as we have seen litigation of any significant amount is a concern (i.e., Whirlpool). I want to put you at ease. MNTA is indemnified by NVS from legal judgments arising from the sale of generic Lovenox (below). Section 12 (page 55) of http://sec.gov/Archives/edgar/data/1235010/000104746904007521/a2130432zex-10_4.txt


    12. INDEMNIFICATION

    12.1. SANDOZ INDEMNIFICATION OF MOMENTA.

    The Sandoz Parties shall indemnify, defend and hold harmless the Momenta Indemnified Parties from and against all losses, costs, damages, judgments, settlements, interest, fees or expenses (including all reasonable attorneys' fees, experts' or consultants' fees, expenses and costs) ("LIABILITIES") awarded to a Third Party against any Momenta Indemnified Party, or that may be incurred or paid by any Momenta Indemnified Party in the defense or compromise of legal or equitable claims asserted by a Third Party, arising out of or resulting from (a) any breach of any obligation by Sandoz or BCWI hereunder, (b) any misrepresentation by Sandoz or BCWI hereunder (including but not limited to any such breach by Sandoz or BCWI of Article 9 - Warranties), (c) any Patent Litigation, (d) any property damage or personal injury (including, without limitation, death) resulting from the development, use, manufacture, sale, offering for sale or importation of the Product by Sandoz, its Affiliates or their Third Party contractors or distributors, or (e) any claims or demands related to the Product that are commenced by [**] any Third Party against any Momenta Indemnified Party based on the activities of Momenta or the Sandoz Parties (including those undertaken by Affiliates or Third Parties on behalf of Momenta or the Sandoz Parties) [**] pursuant to this Agreement; PROVIDED, HOWEVER, that the Sandoz Parties shall have no obligation to indemnify the Momenta Indemnified Parties against Liabilities under (a) through (e) to the extent that such Liabilities arise from any Third Party legal or equitable claim that is subject to Momenta's obligation to indemnify, defend, and hold the Sandoz Indemnified Parties harmless under Section 12.2.


    12.2. MOMENTA INDEMNIFICATION OF SANDOZ.

    Momenta shall indemnify, defend and hold harmless the Sandoz Indemnified Parties from and against all Liabilities awarded to a Third Party against the Sandoz Indemnified Parties or that may be incurred or paid by any of the Sandoz Indemnified Parties in the defense or compromise of legal or equitable claims asserted by a Third Party, arising out of or resulting from (a) any breach of any obligation by Momenta hereunder, including, without limitation, the covenant in Section 9.4, (b) any misrepresentation by Momenta hereunder (including but not limited to any such breach by Momenta of Article 9 - Warranties) of this Agreement, or (c) any actual misappropriation by any Momenta Indemnified Party of any Third Party trade secret or know-how, provided that, (i) with respect to actual misappropriation, there has been a final adjudication of liability for misappropriation by a court of competent jurisdiction, or, (ii) with respect to misappropriation that has been alleged but not finally adjudicated, there is a settlement with a Third Party which the Parties determine by mutual agreement constitutes an acknowledgement by Momenta of actual misappropriation. (either case under (i) or (ii) being a "FINAL MISAPPROPRIATION DETERMINATION"). If there is a dispute between the Parties as to whether a settlement constitutes such an acknowledgement, nationally-recognized outside counsel not regularly employed by any Party or their Affiliates who is mutually acceptable to the Parties shall be retained to resolve such dispute. In the event that Sandoz has, pursuant to the provisions of Section 12.1, incurred Liabilities with respect to an actual or alleged misappropriation by any Momenta Indemnified Party of any Third Party trade secret or know-how and a Final Misappropriation Determination occurs, Momenta shall, in addition to indemnifying the Sandoz Indemnified Parties for such Liabilities incurred by them pursuant to subsection (c) of this Section 12.2, reimburse Sandoz for any Liabilities which Sandoz previously paid to or incurred on behalf of any of the Momenta Indemnified Parties that are allocable to the misappropriation claim that gave rise to the Final Misappropriation Determination.
     
  2. CubbieBlue

    CubbieBlue Member

    Why not? Just curious. Thanks for the find.